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Abstract  
Objective: To determine the patterns of use of prophylactic heparin 
in different specialty hospital in Sulaimani province -Iraqi Kurdistan, in 
patients at risk of VTE, and compare it with international trends to establish 
a protocol or an algorithm to start using prophylactic heparin in our 
hospitals. 
Methods: This discriptive study was conducted from August 2011 to August 
2012. Three hundred patients from three hospitals in Sulaimaniwere 
studied.The patient with high risk of thrombotic event (TE) selected from 
different specialities. No patients with heparin prophylaxis were excluded in 
the study.Data were collected according to special questioner form. The type 
of heparin used was unfractionated heparin. 
Results: Most of the patients in all three hospitals were female (58%, 100%, 
61%), in General Medical hospital, Gynaecology hospital and Surgical 
hospital respectively. Most of the medical patients were above the age of 40 
(71%), while In Gynaecology hospital 69% of patients were below 40 years.  
All of the patients in three different hospitals had risk factors; Surgical and 
Gynaecological patients had major risk factors by (80% and 82% 
respectively). Compared to international standards, heparin prophylaxis was 
under used in all three hospitals (21%, in medical, 18% in Gynaecology and 
12% in surgical hospital). 
Conclusion: Despite the existence of comprehensive consensus guidelines 
for the prevention and treatment of VTE, thromboprophylaxis remains 
underused in our different speciality hospitals. Therefore, we need to 
improve thrombotic risk-assessment methods, familiarisation of clinicians 
with current best practice, and facilitation of appropriate prescribing of 
prophylaxis (establishing local hospitals guidelines). 
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Introduction 
A classical venous thrombus as in deep vein thrombosis (DVT), can 
embolizeand becomes a life-threatening pulmonary embolism (PE). 
Thromboembolism (VTE or DVT/PE) can refer to DVT and/or PE.1 Venous 
thromboembolism results from a combination of hereditary and acquired risk 
factors, also known as thrombophilia or hypercoagulable states. In addition, 
vessel wall damage, venous stasis, and increased activation of clotting 
factors first described by Rudolf Virchow more than a century ago still 
remain the fundamental basis for our understanding of thrombosis.2Hospital-
based epidemiologic data suggest that VTE affects one in 1,000 
personsyearly in North America and Europe, but this incidenceis likely an 
underestimate because an unknown number of patients with this condition 
are undiagnosed or misdiagnosed.Pulmonary embolism is estimated to cause 
50,000 deathsin the United States every year. Most deaths that are 
directlyattributable to acute PE that occur rapidly before the diagnosiscan be 
confirmed and effective treatment implemented,which makes prevention in 
the high-risk patient imperative.3 
In the condition known as thrombophilia, VTE is recurrentand can 
result in significant disability or death, which in manycases happens late in 
the course of the disease from thromboembolicpulmonary hypertension and 
corpulmonale. Venous thromboembolism occurs more often in 
Caucasiansthan in other races, and its risk increases with age, althoughthe 
disease is seen in all ages, even children.4 
The prevalence of VTE, however,appears to be steady and may 
actually be increasing. Possibleexplanations for this increase includes an 
aging population andlonger survival of many patients with 
cancer.5Frequently pulmonary embolism is diagnosed post-mortem. For 
those reasons, the best approach to avoid morbidity & unexpected mortality 
from venous thromboembolism is prophylactic use of anticoagulants in high-
risk patients.2 
Patients with VTE generally have two or more risk factors, and the 
effects of multiple risk factors on VTE risk are additive. The type and 
duration of prophylaxis depends on whether the risk factors are transient 
(e.g., trauma, surgery, infection, the postpartum period) or persistent (e.g., 
advanced age, obesity, history of VTE, thrombophilia). Patients admitted to 
hospital are at particular risk of VTE, and the risk remains elevated after 
discharge.6 
Venous thromboembolism is the third most common cardiovascular 
illness after acute coronary syndrome and stroke. Although the exact 
incidence of VTE is unknown, it is believed there are approximately 1 
million cases of VTE in the United States each year, many of which 
represent recurrent disease.  Nearly two thirds of all VTE events result from 
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hospitalization, and approximately 300, 000 of these patients die. Pulmonary 
embolism is the third most common cause of hospital-related death and it is 
the most common preventable cause of hospital-related death. Most 
hospitalized patients have at least one or more risk factors for VTE. Long-
established and well-known cardiovascular risk factors including 
hypertension, diabetes mellitus, cigarette smoking, and high cholesterol 
levels have been linked to acute PE.7 
Risk factors for VTE are well known. Patients with VTE generally 
have two or more risk factors, and the effects of multiple risk factors on VTE 
risk are additive. The type and duration of prophylaxis depends on whether 
the risk factors are transient (e.g., trauma, surgery, infection, the postpartum 
period) or persistent (e.g., advanced age, obesity, history of VTE, 
thrombophilia). Patients admitted to hospital are at particular risk of VTE, 
and the risk remains elevated after discharge. This is particularly important 
in view of the current trend towards reducing the duration of inpatient stay, 
and suggests that patients will increasingly be discharged while still at risk. 
Furthermore, clinical events occurring after discharge from hospital can give 
the false impression of a declining risk of VTE related to 
hospitalisation.8Thromboembolic prophylaxis remains a significant problem 
and is obviously incompletely understood. It would appear, however, that at 
present the information available implies several points. First, administration 
of low-dose heparin is efficacious in preventing deep vein thrombosis and 
pulmonary emboli in most general surgical patients who are at risk for 
thromboembolic complications. Second, low-dose heparin probably works 
by augmenting the effect of the naturally occurring inhibitor to Factor Xa. 
Third, patients in whom surgical operations are done and extensive tissue 
dissection or postoperative immobilization (such as hip arthroplasties) is 
required are probably not protected by low-dose heparin administration; full 
anticoagulation with warfarin or treatment with one of the platelet anti-
aggregating agents should be carried out. Fourth, any form of anticoagulation 
carries some risk of bleeding complications, but it appears that the incidence 
of major bleeding complications is not significantly greater in the treatment 
groups.9 
 
Aim of the study 
To describe the practice of prophylactic heparin use in different 
specialty hospitals inSulaimani province –Northern Iraq, in thosepatients 
who are at risk of VTE, and compare with different studies in the world to 
establish a draft or an algorithm to start using prophylactic heparin in our 
hospitals. 
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Patients and Methods 
This was a prospective studycarried out for 300 patients from three 
different hospitals and different specialities (medical,surgery, orthopaedics, 
gynaecology and obstetric), the data was collected fromAugust 2011 to 
August 2012.The patients were randomly selected.All patients had verbal 
consents taking to participate in this study. All ages and both genders were 
included in this study. The permission had been taken from directorate of 
health in Sulaimani governorate for all three hospitals. 
Special questioner designed and appropriately filled up for each 
patient, that include (personal details, length of hospital stay, presence of risk 
factors and using of prophylactic heparin).The type of heparin used in this 
study was mostly unfractionated heparin and low molecular weight (LMW) 
heparin. 
 
Results 
The study populationwere 300 patients, one hundred patients in each 
hospital; most of the patients in all three hospitals were female 
(58%,61%,and 100%), in general medical hospital, surgical hospitaland 
gynaecology hospital,respectively.Most of the patients in three different 
hospitals were from inside the Sulaimani city (76% from general medical 
hospital, 62% from gynaecology hospital, and 52% fromsurgicalhospital, 
Table 1. 
Regarding age distribution; 71% of the patients were above 40 years 
in general hospital, 69% of the patients were below 40 years in gynaecology 
and obstetrics hospital, and 57% were above 40 years of age in surgical 
hospital, Table 2.  
As far as the length of stay in the hospital was concern; patients in 
medical hospital stayed more than surgical and gynaecological hospital (55% 
stayed more than 4days in medical hospital compare with 38% and 39% in 
gynaecology and surgical hospital respectively), Table 3. 
The co-morbidity was 59% of surgical patients, 43% of medical 
patients and only in 22% of gynaecology patients, Table 4. 
Six percentages of patients in medical hospital, 76% of patients in 
gynaecology hospital, and 73% of patients in surgical hospitalhad of history 
recent operation, Table 5. 
Regarding the presence of risk factors in general medical 
hospital,58% of the patients had minor risk factor, and 42%patients had 
major risk factors, P > 0.05. In gynaecology Hospitals, 82% had major risk 
factors, and 18% had minor risk factors, P < 0.01. In surgical hospitals 80% 
had majorrisk factors and 20% had minor risk factors, P < 0.01 (Table 6). 
Only21 patients (21%) among selected patients in general medical 
hospital received prophylactic heparin, P < 0.01. While in gynaecology and 
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surgical hospitals, only 18%and 12% were receiving prophylactic heparin 
treatment, P < 0.01 and P < 0.01 respectively (Table 7). The type of heparin 
used was mostly unfractionated compare with LMW, 52% in general 
medicine hospital, 83% in gynaecology and obstetric hospital, and 75% in 
surgery and orthopaedic hospital Table 8. 
The authors found that, some of the patients were having 
contraindication for the using heparin (fifteen percentages in medical 
hospital, 18% in gynaecology hospital, and 19% in surgical and orthopaedic 
hospital, Table 9. 
  
Discussion  
According to this study most of the patients in the three different 
hospitals were form inside the Sulaimani city.(76% in medical hospital, 
62% in gynaecology hospital, and 52% in surgical hospital were from inside 
the city), this might reflect that people of big cities have higher risk of VTE, 
rather than rural area.10 
Regarding length of hospital stay; patients in medical department 
stayed in hospital more than surgical and gynaecological hospital, (55% 
stayed >4days in medical hospital compare with 38% and 39% in 
gynaecology and surgical hospital, respectively).Females were predominant 
in all three hospitals over male, (58%, 100%, and 61%), in general medical 
hospital, gynaecology hospital and surgical hospital respectively. This 
finding issimilar to the results of other studies done in this field especially.11 
All patients in this study were at a risk for VTE (minor or major), 
only 21% (21 patients) among patients with risk group in medical hospital 
received treatment with prophylactic heparin, this washigher although not 
significantly than gynaecology and surgical hospitals, that only (18% and 
12% respectively) were receiving prophylactic heparin treatment, this 
finding are very low in comparison with American college of clinical 
pharmacy guidelines (ACCP).7 
A multinational middle eastern survey of venous thromboembolism 
(VTE) risk and prophylaxis, was assessing 101 hospital in 10 countries, the 
result showed that, 24% of medical patients and 44% of surgical patients at 
risk receiving prophylaxis.12 In another study done inJames Cook University 
Hospital, Middlesbrough, United Kingdom, (improving compliance with 
primary thrombo-prophylaxis (PTP) guidelines in medical patients), showed 
that compliance of using thrombo-prophylaxisincreased from 22% in 2007 to 
47% in 2008(10,11,12). In venous thromboembolism risk and prophylaxis in 
a Saudi hospital, the studyrecommended VTE prophylaxis, was given only to 
16 (35.6%) surgical patients at risk, 12 (26.7%) at-risk medical patients, and 
17 (37.8%) at-risk gynaecology/obstetrics patients, these levels were very 
low compared with this study.2,13,14According to the data in this study, most 
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of those on prophylactic treatment, they were using Unfractionated heparin 
more than LMW heparin, (48%, and 52% in medical hospital), (17% and 
83% in gynaecology hospital), (25% and 75% in surgical hospital). In most 
of other studies suggested that LMW heparin is superior to unfractionated 
heparin.1,13,15In all three hospitals there were nearly the same 
contraindication for using prophylactic heparin ranging from 15-19 %. 
 
Conclusion  
Despite the existence of comprehensive consensus guidelines for the 
prevention and treatment of VTE], thromboprophylaxis remains underused 
in our different speciality hospitals. Reasons for underuse are complex and 
include underestimation of the risks of VTE, underestimation of the impact 
of non-fatal outcomes of VTE, lack of awareness of relevant guidelines, 
absence of local thromboprophylaxis strategies, and concerns about the risk 
of bleeding.We needs to improved thrombotic risk-assessment methods, 
familiarisation of clinicians with current best practice, and facilitation of 
appropriate prescribing of prophylaxis (establish local hospital guidelines). 
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Tables  
Table 1. Gender and residency of study population. 
 
 
General Medical 
 Hospital 
Genecology and 
Obstructive  
Hospital  
 
Surgical and  
Orthopaedics  
Hospital 
No. (%) No. (%) No. (%) 
Gender  
Male 
 
Female 
 
 
42 (42%) 
 
58 (58%) 
 
0 (0%) 
 
100 (100%) 
 
39 (39%) 
 
61(61%) 
Residency  
Inside city 
 
Outside city 
 
76 (76%) 
 
24 (24%) 
 
62 (62%) 
 
38 (38%) 
 
52 (52%) 
 
48 (48%) 
 
Table 2.  Age distribution of study population. 
 
 
 
Age 
 
General Medical 
 Hospital 
Genecology and 
Obstructive  
Hospital  
 
Surgical and  
Orthopaedics  
Hospital 
No. (%) 
 
No. (%) 
 
No. (%) 
 
< 20 years 
 
20 – 40 years 
 
40 – 60 years 
 
> 60 years 
8 (8%) 
 
21 (21%) 
 
36 (36%) 
 
35 (35%) 
22 (22%) 
 
47 (47%) 
 
26 (26%) 
 
5 (5%) 
13 (13%) 
 
30 (30%) 
 
34 (34%) 
 
23 (23%) 
Total  100 (100%)  100 (100%) 100 (100%)  
 
Table 3.  Length of stay in a hospital of study population. 
 
 
 
Length of stay  
in a hospital 
General Medical 
 Hospital 
Genecology and 
Obstructive  
Hospital  
 
Surgical and  
Orthopaedics  
Hospital 
No. (%) 
 
No. (%) 
 
No. (%) 
 
< 4 days 
 
> 4 days 
45 (45%) 
 
55 (55%) 
62 (62%) 
 
39 (39%) 
61 (61%) 
 
39 (39%) 
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Table 4.  Presence of co-morbidities in study population. 
 
 
 
Presence of  
co-morbidities 
General Medical 
 Hospital 
Genecology and 
Obstructive  
Hospital  
 
Surgical and  
Orthopaedics  
Hospital 
No. (%) No. (%) No. (%) 
Yes 
 
No 
43 (43%) 
 
57 (57%) 
22 (22%) 
 
78 (78%) 
59 (59%) 
 
41 (41%) 
 
Table 5.  History of recent surgery in study population. 
 
 
 
History of  
recent surgery 
General Medical 
 Hospital 
Genecology and 
Obstructive  
Hospital  
 
Surgical and  
Orthopaedics  
Hospital 
No. No.  No.  
Yes 
 
No 
6 (6%) 
 
94 (94%) 
76 (76%) 
 
24 (24%) 
73 (73%) 
 
27 (27%) 
 
Table 6.  Presence of risk factors in three hospitals. 
 
 
 
Risk factors 
General medicine Genecology and 
obstetric** 
 
Surgery and orthopae  
** 
No. No.  No.  
Major 
 
Minor 
42 (42%) 
 
58 (58%) 
82 (82%) 
 
18 (18%) 
80 (80%) 
 
20 (20%) 
**= P<0.01 
 
Table 7.  Use of prophylactic heparin in study population. 
 
 
 
Use of prophylactic 
Heparin 
General Medical 
 Hospital** 
Genecology and 
Obstructive  
Hospital** 
 
Surgical and  
Orthopaedics  
Hospital** 
No. No.  No.  
Yes   
 
No 
21 (21%) 
 
79 (79%) 
18 (18%) 
 
82 (82%) 
12 (12%) 
 
88 (88%) 
**= P< 0.01 
Table 8.  Type of heparin used in study population. 
 
 
Type of  
Heparin 
General Medicine 
 
Genecology and 
Obstructive   
 
Surgical and  
Orthopaedics  
No. No.  No.  
LMW 
 
Unfractionated 
10 (48%) 
 
11 (52%) 
3 (17%) 
 
15 (83%) 
3 (25%) 
 
9 (75%) 
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Table 9.  Presence of contraindication in study population. 
 
 
 
Presence of 
contraindication 
 
General Medical 
 Hospital 
Genecology and 
Obstructive  
Hospital  
 
Surgical and  
Orthopaedics  
Hospital 
No. No.  No.  
Yes 
 
No 
15 (15%) 
 
85 (85%) 
18 (18%) 
 
82 (82%) 
19 (19%) 
 
81 (81%) 
 
Appendix 1 (questionnaire) 
Name;     sex;   age;     hospital; 
Address;  date of admission;    date of sample 
collection; 
Duration of hospital stay in days; 
Recent operation;     Yes                     No 
Co-morbidities;        Yes                     No 
Risk factor for TED; 
Major ; 
                        Major surgery 
  Obstetric surgery 
  Preclampcia 
  Malignancy 
  Lower limb problem 
  Reduce mobility 
  Previous DVT 
  Old or new CVA 
  Pregnancy 
Minor ; 
   CVS (IHD, HF) 
     Renal disease (CRF) 
    CCP- HRT 
  Myeloproliferative disease 
  Smoking 
  Obesity 
 Inherited; 
 Family history of DVT 
On prophylactic treatment          Yes                 No 
Type of heparin;    LMWH         Un fractionated heparin 
 
Right dosage;       Yes              No 
Contraindication for TE prophylaxis;       Yes 
 
 
 
 
 
 
